Marker Therapeutics Showcases MAR-T Cell Therapy Advances and MT-601 Clinical Progress in New Corporate Presentation
Reuters
Nov 14
Marker <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases MAR-T Cell Therapy Advances and MT-601 Clinical Progress in New Corporate Presentation
Marker Therapeutics Inc. has released a corporate presentation highlighting developments in its MAR-T cell therapy platform. The company's lead product, MT-601, is designed to target six tumor-specific antigens, offering broad tumor recognition for both blood and solid tumors. The APOLLO Phase 1 clinical trial for MT-601 has shown durable objective response rates in patients with lymphoma who relapsed after anti-CD19 CAR-T cell therapy or for whom CAR-T cell therapy is not an option. MT-601 is currently being studied in dose escalation and expansion cohorts, including disease-specific groups for diffuse large B cell lymphoma (DLBCL). The presentation also notes improvements in manufacturing processes and higher cell potency compared to earlier studies. Marker Therapeutics maintains a strong intellectual property position and has received over $30 million in non-dilutive funding from sources such as the NIH, FDA, and CPRIT. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.